Undisclosed HD Program(s)
Huntington's Disease
PreclinicalResearch & Discovery
Key Facts
About WaVe Life Sciences
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Its core strategy is built on the PRISM® platform, a toolkit for designing and developing stereopure oligonucleotides, including RNA editing and silencing therapies. The company is rapidly advancing a diversified pipeline, with key programs like WVE-006 for Alpha-1 antitrypsin deficiency and WVE-007 (INHBE siRNA) for obesity generating significant clinical interest. Wave is strategically positioning itself at the forefront of next-generation genetic medicines.
View full company profileTherapeutic Areas
Other Huntington's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| SRP-1005 (ARO-HTT) | Arrowhead Pharmaceuticals | Phase 1 |
| PTC518 | PTC Therapeutics | Phase 2 |
| AMT-130 | uniQure | Phase 1/2 |
| Undisclosed Program | Sangamo Therapeutics | Preclinical |
| Pepinemab (VX15/2503) | Vaccinex | Phase 2 |